Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.
Epistemonikos ID: 0f93c4caa6cb29e90bf4467b90e65806e8ddc1e4
First added on: Dec 17, 2025